A groundbreaking study led by researchers at the Sanford Burnham Prebys Medical Discovery Institute has identified potential new therapeutic avenues for patients with Alagille syndrome. Published in Nature Communications, the research utilized zebrafish models to uncover the specific cells and genes necessary for the formation of liver ducts. Patients with Alagille syndrome typically have fewer liver ducts than normal, which leads to severe complications such as jaundice, liver disease, and potentially liver failure.
Alagille syndrome is a rare genetic disorder primarily caused by mutations in the JAGGED1 gene, with a small percentage of cases linked to the NOTCH2 gene. The disorder affects multiple organ systems, but the loss of liver ducts is one of its most defining and debilitating features. Currently, there are no drugs or surgical procedures capable of correcting this structural deficit, making the search for new treatments critical.
The research team focused on understanding how the Jagged protein functions during liver development. It was previously known that Jagged triggers Notch signaling in neighboring cells, a crucial step in organ development. However, by using mutant zebrafish, the scientists discovered that Jagged signals originate from an unexpected source: endoderm-derived cells within the liver itself. This finding contrasts with previous studies in mice, which suggested that duct malformation was due to insufficient signals from hepatic vein cells.
This discovery is significant because pinpointing the exact location and cell type that require Jagged expression provides a clear target for future therapeutics. By understanding where the deficiency lies, researchers can develop strategies to compensate for the lack of Jagged function. Furthermore, the study revealed that duct cells are lost due to this lack of function, rather than simply being malformed. This insight shifts the focus toward regenerative therapeutic approaches aimed at replacing the lost duct cells.
The research team is now exploring the possibility of using zebrafish to screen for potential drugs that could alleviate the pathologies caused by the loss of Jagged function. As gene therapy technologies like CRISPR/Cas9 continue to advance, these findings bring the medical community one step closer to delivering genetic corrections for JAGGED1 mutations, offering hope to the 10 to 30 percent of patients who eventually require a liver transplant.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.